Solutia Pharmaceutical to Install World-Class Containment Facility for the synthesis of highly potent Active Pharmaceuticals

19-Jul-2002

FARNBOROUGH, U.K., July 17, 2002 - Solutia Inc.'s Pharmaceutical Services Division (Solutia PSD) will construct a state-of-the-art facility for the synthesis of highly potent active pharmaceutical ingredients (APIs). This expansion will provide pharmaceutical companies with an important resource enabling the contract manufacture of highly potent drugs to be carried out to the highest standards of quality and efficiency. Commissioning of the new facility is planned for first quarter, 2003.

"Oncology remains the largest area of unmet clinical need in pharmaceutical research," says Ed Robinson, president of Solutia PSD. "More than 25 percent of current late-development compounds require contained handling, and this ratio is increasing as more highly potent compounds progress through development. Our customers tell us that they see an acute shortage of high-quality facilities, and we believe that we can help solve their problems."

"The new facility will enable us to provide a range of production-scale services that extend from development chemistry to manufacture of production quantities for clinical or commercial use," said Mark Griffiths, director of engineering for Solutia PSD. "This capability fits very well with our current scale of operation for APIs, which supports non-potent parts of the synthesis process."

The new facility continues the expansion of Solutia PSD's capabilities, furthering its strategy of offering seamless drug development services from bench to market. "High-potency capability strongly complements our business strategy for the development of chemistry services and fulfills yet another part of our integrated investment plan for Solutia PSD," said Robinson. "We anticipate that our new containment facility will become a strong component of our overall chemistry portfolio, alongside process research and development services, analytical development services and cGMP supply of APIs."

The new facility will be based at Solutia PSD's existing site in Marly, Switzerland. Additional Solutia PSD sites include Aarau, Neuland and Bubendorf in Switzerland, and Seattle, Washington, U.S.A.

https://www.bionity.com/en/news/12171/solutia-pharmaceutical-to-install-world-class-containment-facility-for-the-synthesis-of-highly-potent-active-pharmaceuticals.html